The COVID-19 pandemic has challenged the research world to think differently about the conduct
of global clinical trials. Research has rapidly evolved to “virtual” environments, forcing sponsors and
clinical research organizations (CROs) to think differently about the way in which clinical trials are
approached in the areas of site selection, study start-up, patient recruitment, monitoring, safety
oversight, and data integrity.
The information contained within this document may be useful to teams conducting or planning
COVID-19 clinical studies at any phase.